Gestational trophoblastic disease (GTD) is a collection of illnesses connected to pregnancy that result from aberrant placental trophoblast growth. Some GTD patients experience the rare but possibly fatal consequence of hyperthyroidism, which calls for prompt diagnosis and treatment. There is very little research on hyperthyroidism in GTD. This review examines the epidemiology, pathogenesis, and treatment of this phenomenon. The pathogenesis of hyperthyroidism in GTD has received extensive research. The trophoblastic tissue of the placenta secretes an excessive amount of hCG, which is structurally related to thyroid-stimulating hormone and has increased thyrotropic activity. Worldwide, there are different rates of hyperthyroidism in GTD, with lower rates related to high prenatal screening uptake and early GTD discovery. We were unable to pinpoint any specific risk factors for hyperthyroidism in GTD. Although surgical removal of the uterus can definitively treat hyperthyroidism, serious consequences in GTD have been recorded, including thyroid storm-induced multi-organ failure, ARDS, and pulmonary hypertension. To stop the onset of hyperthyroidism and the difficulties that go along with it, early GTD identification is essential. Women receiving surgery for GTD should be aware of hyperthyroidism as a critical postoperative factor that needs to be adequately managed. Future research should examine the elements contributing to hyperthyroidism in GTD as this may help identify high-risk female patients early. Keywords: [Gestational trophoblastic disease, Molar pregnancy, Hyperthyroidism, Hydatidiform mole, Pregnancy]